Immunovaccine Chief Medical Officer Dr. Gabriela Rosu to Present at the Oncology Meeting Innovations (OMI) Annual Summit on Hematologic Malignancies
Dr. Rosu will present an overview of Immunovaccine’s lead candidate, DPX-Survivac, including the clinical strategy for evaluating this program in diffuse large B cell Lymphoma. Details of Dr. Rosu’s presentation are as follows:
|Name:||DPX Survivac - a Novel, Long-lasting, T Cell Activating
|Date:||Saturday, March 17, 2018|
|Time:||11:45 am PT|
|Location:||The MacDonald Room, Fairmount Chateau Whistler, 4599
Chateau Blvd., Whistler, British Columbia V0N 1B4 Canada
The conference, sponsored by Oncology Meeting Innovations, is designed to engage top researchers and practicing clinicians to discuss emerging clinical data, current treatment options, and the future treatment landscape for hematological malignancies. Indications covered at the meeting will include Chronic Lymphocytic Leukemia, Multiple Myeloma, aggressive and indolent Lymphomas and Acute Leukemias.
Oncology Meeting Innovations (OMI) is part of
DPX-Survivac consists of survivin-based peptide antigens formulated in the Company’s proprietary DepoVax™ delivery platform. DPX-Survivac is thought to work by eliciting a cytotoxic T cell immune response against cells presenting survivin peptides. Survivin, recognized by the
Immunovaccine Forward-Looking Statements
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals.
T: (312) 961-2502 E: email@example.com
Pierre Labbé, Chief Financial Officer
T: (902) 492-1819 E: firstname.lastname@example.org
O: (415) 513-1284
T: (415) 515-4572 E: email@example.com
Source: Immunovaccine Inc.